Loading
HCW Biologics
HCW Biologics is a Florida company making fusion proteins that act on the immune system, mainly for inflammatory diseases. For cancer, its lead product, HCW11-018b, is an injection under the skin that steers the body's T cells onto solid tumours and is being prepared for a first trial in people.
Also called: HCW Biologics Inc.
Overview
HCW Biologics Inc., based in Miramar, Florida and listed on Nasdaq as HCWB, describes itself in its 2026 S-1 as a clinical-stage company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune and proinflammatory diseases, cancer and senescence-associated dysplasia. Its founder and chief executive, Hing C. Wong, led the development of the IL-15 receptor agonist that was sold to ImmunityBio in 2017 and later approved for BCG-unresponsive non-muscle invasive bladder cancer.
In oncology, the filing names HCW11-018b, a tetravalent T-cell engager given by subcutaneous injection to treat solid tumours. After a Type B pre-IND meeting with the FDA in July 2026, the company says it is preparing an IND for a Phase 1 trial in solid tumours, to be filed in the first half of 2027. Its most advanced clinical compound is an IL-2 fusion protein complex in a Phase 1 trial in alopecia areata, and it has agreed to distribute a reagent molecule for cell therapy manufacturing through Akron Biotech.
Headquarters
Miramar, FL, US
Scorecard
All companies#772of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
Biotech · HCWB
Stage
Public
Website
Products
1PreclinicalTetravalent T-cell engager (fusion protein, subcutaneous)
HCW11-018b is an experimental injection under the skin designed to direct the body's T cells against solid tumours. HCW Biologics plans to ask the US regulator in 2027 for permission to begin its first trial in people.
Notes
- Read from the S-1 filed on EDGAR on 2 October 2026 (prospectus summary and cover page) on 4 November 2026. Only the oncology programme is recorded as a product; the inflammation programmes are described without codes. Founding year not read.
Connected
3fronts
technologies
drugs
PreclinicalTetravalent T-cell engager (fusion protein, subcutaneous)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
hcwbiologics.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/